New RNA-based drug enters Australian trial for severe pre-eclampsia

Katie James endured two critical bouts of pre-eclampsia, the first resulting in an emergency caesarean and intensive care, and the second leading to the birth of a premature infant who died from a brain bleed. After her obstetrician suggested further care, she met Professor Shaun Brennecke, who has managed a trial of an aspirin regimen for high-risk women and now leads a Phase 1b study of CBP4888, an RNA-based drug developed by Comanche Biopharma.

The medication aims to curb the placenta’s excess production of a protein that damages blood vessels, a key factor in pre-eclampsia. Australia was selected for the trial because local clinicians can measure the protein’s levels. The study will evaluate dosage over two to three years, with plans for broader international trials if results are positive, and the manufacturer intends to keep the drug affordable for low- and middle-income countries.